We've found
6,982
archived clinical trials in
Endocrine
We've found
6,982
archived clinical trials in
Endocrine
A Short Term Evaluation of a Structured Weight Loss Plan in Overweight and Obese Adults
Updated: 4/2/2018
A Short Term Evaluation of a Structured Weight Loss Plan in Overweight and Obese Adults
Status: Enrolling
Updated: 4/2/2018
A Short Term Evaluation of a Structured Weight Loss Plan in Overweight and Obese Adults
Updated: 4/2/2018
A Short Term Evaluation of a Structured Weight Loss Plan in Overweight and Obese Adults
Status: Enrolling
Updated: 4/2/2018
Click here to add this to my saved trials
Vitamin D Deficiency, Insulin Resistance and FGF-23
Updated: 4/2/2018
Impact of Vitamin D Deficiency on Insulin Resistance and the Regulation of FGF-23
Status: Enrolling
Updated: 4/2/2018
Vitamin D Deficiency, Insulin Resistance and FGF-23
Updated: 4/2/2018
Impact of Vitamin D Deficiency on Insulin Resistance and the Regulation of FGF-23
Status: Enrolling
Updated: 4/2/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials